Opinion

Video

The Impact of Tumor Heterogeneity in Ovarian Cancer

Author(s):

Bradley J. Monk, MD, FACS, FACOG

A panelist discusses how tumor heterogeneity (both spatial and temporal) affects molecular testing reliability in ovarian cancer, highlighting that although most biomarkers show little heterogeneity, newer approaches like liquid biopsies can provide a more comprehensive genetic profile of the entire tumor burden.

Video content above is prompted by the following:

Impact of Tumor Heterogeneity on Testing Reliability

Although ovarian cancer shows relatively limited spatial and temporal heterogeneity compared to other cancers, considerations include the following:

  • More recent biopsies are preferred for testing when available.
  • Blood-based testing (liquid biopsies) can provide genomic information by sampling circulating tumor DNA from the entire tumor burden.
  • Cell-free DNA testing is increasingly useful but cannot yet replace tissue-based testing for protein expression markers like HER2 and folate receptor alpha.

Research continues to develop more comprehensive testing through liquid biopsy approaches.

Related Videos
4 experts are featured in this series.
1 expert in this video
5 experts in this video
5 experts in this video
4 experts are featured in this series.
1 expert in this video
Related Content
Nurse talking to Black patient in waiting room | Image credit: DC Studio - stock.adobe.com
May 10th 2025

IPF Trial Practices Often Exclude Certain Patients, Perspectives

Jared Kaltwasser
Clinical trials for idiopathic pulmonary fibrosis could benefit from improved patient engagement to include diverse perspectives and inclusive practices.
managed care cast logo
December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick
On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.
AJMC
May 9th 2025

Health Outcomes Under Full-Risk Medicare Advantage vs Traditional Medicare

Kenneth Cohen, MD Boris Vabson, PhD Jennifer Podulka, MPAff Omid Ameli, MD, DrPH Kierstin Catlett, PhD Nathan Smith, PhD Megan S. Jarvis, MS Jane Sullivan, MPH Caroline Goldzweig, MD, MSHS Susan Dentzer, MS
Physician groups under 2-sided risk–based Medicare Advantage provide care associated with higher quality and efficiency compared with care by these same groups under fee-for-service Medicare.
Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi
December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.
FDA approval graphic | Image Credit: wladimir1804 - stock.adobe.com
May 9th 2025

FDA Approves First Treatment for KRAS-Mutated Recurrent LGSOC

Brooke McCormick
FDA approves the first treatment for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC), offering new hope for patients with this condition.
AJMC
May 9th 2025

Predictive Models for Low Birth Weight: A Comparative Analysis of Algorithmic Fairness–Improving Approaches

Clare C. Brown, PhD, MPH Horacio Gomez-Acevedo, PhD Benjamin C. Amick III, PhD J. Mick Tilford, PhD Keneshia Bryant-Moore, PhD, APRN Michael Thomsen, PhD
This study compared 6 algorithmic fairness–improving approaches for low-birth-weight predictive models and found that they improved accuracy but decreased sensitivity for Black populations.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo